New study tracks bleeding drug in kids
NCT ID NCT07404644
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study in Japan looks at how safe and effective Vonvendi (rVWF) is for children under 18 with Von Willebrand Disease, a bleeding disorder. About 13 kids will receive the drug as part of their normal care for bleeding episodes or before surgery. Researchers will monitor side effects and how well the drug controls bleeding for one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New shot aims to tame bleeding disorder in small trial
- New algorithm aims to stop dangerous bleeding in VWD patients
- Family history questions may improve bleeding disorder detection in kids
- New drug aims to lighten heavy periods for bleeding disorder patients
- UK doctors look back at real-world use of new VWD drug
- New study aims to uncover hidden bleeding disorder in egyptian kids